key: cord-0283570-5j6t6jzl
authors: Richardson, J. R.; Goetz, R.; Mayr, V.; Lohse, M. J.; Holthoff, H.-P.; Ungerer, M.
title: SARS-COV2 mutant-specific T cells and neutralizing antibodies after vaccination and up to 1 year after infection
date: 2021-09-14
journal: nan
DOI: 10.1101/2021.09.07.21262725
sha: 79e800fbd7286683999a92c845ec1ea62faf6540
doc_id: 283570
cord_uid: 5j6t6jzl

Objective: We investigated blood samples from fully SARS-CoV2-vaccinated subjects and from patients up to one year after infection with SARS-CoV2, and compared short and long term T cell and antibody responses, with a special focus on the recently emerged delta variant (B.1.617.2). Methods and Results: In 23 vaccinated subjects, we documented high anti-SARS-CoV2 spike protein receptor binding domain (RBD) antibody titers. Average virus neutralization by antibodies, assessed as inhibition of ACE2 binding to RBD, was 2.2-fold reduced for delta mutant vs. wt RBD. Specific CD4+ T cell responses as measured using stimulation with peptides representing wt or alpha, beta, gamma and delta variant SARS-CoV2 entire spike proteins by flow cytometric intracellular cytokine staining, did not differ significantly between vaccinees. One year post infection in one of the earliest SARS-CoV2 populations in the Western world, mean specific antibody titers were lower than in vaccinees; ACE2 binding to delta mutant vs. wt RBD was 1.65-fold reduced. T cell responses, especially interferon gamma expression, to mutant SARS-CoV2 spike were significantly reduced compared to those in vaccinees. Conclusion: Strong T cell responses occurred for wildtype and mutant SARS-CoV2 variants, including delta (B.1.617.2), in fully vaccinated individuals, whereas they were partly reduced 1 year after natural infection. Antibody neutralisation of delta mutant was reduced compared to wt, as assessed in a novel inhibition assay with a finger stick drop of blood. Hence, immune responses after vaccination are stronger compared to those after naturally occurring infection, pointing out the need of the vaccine to overcome the pandemic.

Since December 2019, the SARS-CoV-2 pandemic has caused global health problems, leading to more than 4 million deaths (Johns Hopkins University database) and therefore demanding rapid development of vaccines for protection against the virus. Vaccine (AZD1222) (Oxford-AstraZeneca; chimpanzee adenoviral vectored) have been approved globally and have been most frequently used in Europe. All of these vaccines have been designed to raise antibodies and T lymphocyte responses to the spike (S) protein, and all include S sequences derived from the first reported sequence from Wuhan in January 2020 (5) .

Similar to other RNA viruses, SARS-CoV-2 is subject to progressive mutational changes.

The pandemic spread leads to a huge extent of viral replication, increasing the odds that adaptive mutations will occur, which could lead to selective± advantages, e.g. enhanced binding to human cells or immune escape from neutralizing antibodies (6) . The S protein is a type-1 transmembrane glycoprotein, which may assemble into trimers (7) . It is composed of two parts: the S1 domain bears the receptor-binding domain (RBD) and mediates cell binding via the angiotensin-converting enzyme-2 (ACE2), while the S2 domain completes membrane fusion, allowing the viral RNA to access the host cell cytoplasm to initiate viral replication.

The ACE2-RBD interaction is mediated by a small 25 amino acid patch, which becomes accessible when the RBD moves into an upper direction (8; 9) . Mutations in this region are most concerning:

The alpha (B.1.1.7), beta (B.1.351), gamma (P.1) and delta (B.1.617.2) variants have been classified as variants of concern and have by far superseded the wt. These all have the potential to modulate ACE2-RBD binding affinity, potentially leading to an increased transmissibility. In addition, the variants´ mutated amino acid residues can also modulate neutralization of SARS-CoV2 by naturally or vaccine induced antibody responses.

In this study, we therefore compared the immune responses of individuals less than 2 months or 1 year after a naturally occurring infection with SARS-CoV2 with those of subjects who had been completely vaccinated (at least two weeks after the last dose) with either mRNA-based (BNT162b2, Comirnaty (Pfizer-BioNTech), mRNA-1273 (Moderna)) or vectorbased vaccines (ChAdOx1 nCoV-19 -Vaxzevria, AZD1222, Oxford-AstraZeneca). We investigated anti-S and anti-N protein antibodies plus inhibition assays of ACE2 binding to wildtype vs. delta mutant RBD proteins (as a correlate of neutralizing potency) and S proteinspecific T cell responses to wt and mutant S protein-derived peptide pools. The study was intended to provide further insight into immune responses after naturally occurring infections versus vaccination regarding the most concerning mutant virus variants with a special focus on the delta mutant.

Blood was collected for peripheral blood mononuclear cell (PBMC) isolation (in S-Monovettes® K3 EDTA (Sarstedt) or equal), as well as for serum isolation (S-Monovettes® Serum (Sarstedt) or equal). The blood was diluted with an equal volume of PBS (Corning) containing 2% fetal bovine serum (FBS; Gibco; heat-inactivated; from Brazil). PBMCs were obtained by density gradient centrifugation using SepMate™-50 tubes (Stemcell Technologies) filled with Lymphoprep™ density gradient medium (Stemcell Technologies) according to the manufacturer's instructions. After the isolation, the PBMCs were stained with Acridine Orange and DAPI (solution 18, Chemometec), counted using the NC-250 cell counter (Chemometec), frozen in FBS with 10% DMSO, and stored in liquid nitrogen for at least one week before further experiments. Blood collected for serum isolation was centrifuged 10 min at 2,000xg. Serum was transferred into Eppendorf tubes and frozen at -20°C until use for further experiments.

Ex vivo T-cell responses were analyzed by intracellular cytokine staining (ICS) after stimulation. To this aim, PBMCs were thawed and rested in T cell medium (TCM; RPMI1640 (+GlutaMAX +HEPES, Gibco) + 8% FBS + 1x Penicillin/Streptomycin (Gibco)) containing 1µg/mL DNase (Sigma) for 4-6 hours at 37°C with 5% CO 2 prior to stimulation. Afterwards, 0.5 -1.5x10 6 cells per well (96-well plate) were stimulated with 5 µg/mL of the peptide mixes. DdH 2 O with or without DMSO (depending on the solvent of the peptides) and PMA (10µg/mL)/ Ionomycin (1µM) (both from Sigma) were added as negative and positive controls, respectively. The protein transport inhibitor Brefeldin A (10µg/mL, eBioscience) was added simultaneously and cells were incubated for 14-16h at 37°C, 5% CO 2 . The next day, cells were washed in PBS + 0.5% BSA (Sigma) and stained extracellularly for 20 min at 4°C (Table 1) . Thereafter, cells were fixed with IC Fixation Buffer (Intracellular Fixation & Permeabilization Buffer Set, eBioscience) for 30 min at room temperature. Cells were washed and 1x permeabilization buffer (dilute 10x permeabilization buffer from the intracellular fixation & permeabilization buffer set, eBioscience with 9x ddH20) was added and incubated for 5 min, before intracellular staining for 30 min at room temperature (Table   1 ). Subsequently, cells were washed twice, resuspended in PBS + 0.5% BSA and analyzed with the MACSQuant10 flow cytometer (Miltenyi).

The data analysis was performed with FCS Express 7 (V. 7.06, De Novo Software). All results were audited, and responses were defined as positive if the percentage of markerpositive cells after peptide stimulation was ≥ two-fold compared to the negative control and >20 marker-positive cells were recorded. The frequency of the negative controls was subtracted from the frequency of marker-positive cells. The complementary DNA sequences adapted for hamster codon usage were produced synthetically by GeneArt (Life Technologies) by adding the signal sequence METPAQLLFLLLLWLPDTTG at the beginning and cloned into the plasmid vector All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Scientific # 66380) against phosphate-buffered saline (PBS from Roth: 137 mM NaCl, 2.7 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Anti-SARS-CoV2 antibodies in human serum or in a drop of full blood were detected by a two-step incubation antigen sandwich ELISA using the RBD of the S1 protein of the SARS-CoV2 virus. All procedures were performed at room temperature (RT) and incubations were done on a microtiter plate shaker. ELISA plates were coated with 60 µl/ well RBD-His protein preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 14, 2021. ; https://doi.org/10.1101/2021.09.07.21262725 doi: medRxiv preprint and incubated with Strep-POD (Jackson Immunoresearch, #016-030-084) diluted in PBST 1:50000 for 1h. After washing five times, bound POD was detected by incubation with 100 µl/ well of TMB substrate (Thermo Scientific, #34029) until a maximal optical density (OD) of about 1 to 2 was reached. Finally, the colorimetric reaction was stopped with 100 µl/ well stopping solution (1M H 2 SO 4 ) and the OD determined at a wavelength of 450 nm with a reference wavelength of 595 nm in a plate reader. Ratios between IC50s calculated for inhibition of wt vs. delta mutant RBD binding to immobilized ACE2 were used for further analysis. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

All procedures were performed at room temperature (RT) and incubations were done on a microtiter plate shaker. ELISA plates were coated with 60 µl/ well RBDwt protein or RBDdelta with 2 µg/ml in coating buffer (50mM carbonate buffer, Na2CO3/NaHCO3, pH9.6) for 1 h. Ratios between IC50s calculated for inhibition of ACE2 binding to immobilized wt vs. delta mutant RBD were used for further analysis.

Statistical analysis was performed using SPSS software version 26. Statistical differences were determined using one-way ANOVA with Tukey's post-hoc test in case data were

SARS-CoV2 mutant spike RBD and nucleocapsid wild type and mutant proteins were expressed in mammalian cells and purified to > 99% purity to be used in the assays. Figures   1A + B show representative examples for the purity after the affinity column and after subsequent dialysis, respectively.

All vaccinees showed clear antibody responses against wildtype SARS-CoV2 RBD. This finding occurred regardless of the type of vaccine used -as shown in Figure 2A . We did not detect any anti-nucleocapsid protein antibodies in any vaccinated subjects, except in one subject which had suffered from naturally occurring infection before vaccination.

In comparison, we assessed short-term and long-term immune responses in patients´ blood samples up to one year after infection with SARS-CoV2 (Figure 2A) . We found specific anti-SARS-CoV2 RBD spike protein and anti-nucleocapsid antibody titers in 90% investigated individuals, as assessed by comparing these titers with non-specific protein binding on the plates. Titers in vaccines were significantly higher than in subjects after natural infection, regardless of the time interval since infection.

Also, inhibition of either wildtype SARS-CoV2 RBD or delta mutant RBD binding to ACE2 was investigated as a correlate for antibody neutralizing potency. We found significantly reduced mean IC50-values for the delta mutant -see Figures 2B-E. Figure 2B shows absolute IC50-values for the inhibition of ACE2 binding to immobilized wt vs. delta mutant RBD, and Figure 2C absolute IC50-values calculated for the inhibition of wt vs. delta mutant RBD binding to immobilized ACE2. The ratios between IC50-values calculated for inhibition of ACE2 binding to immobilized wt vs. delta mutant RBD are shown in Figure 2D . Figure 2E shows ratios between IC50-values calculated for inhibition of wt vs. delta mutant RBD binding to immobilized ACE2. Both, vaccinees and naturally infected subjects showed significantly (p < 0.001 by sign testing) reduced mean IC50-values for the delta mutant, with an average 2,2-fold reduction in vaccinees and an 1,65-fold average reduction in the All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 14, 2021. ; https://doi.org/10.1101/2021.09.07.21262725 doi: medRxiv preprint naturally infected group. Figure 2F shows that results using a drop of finger-stick full blood (about 30 µl) were well comparable to those using sera obtained by venous puncture.

In summary, results from the inhibition assays were comparable, regardless whether RBD or ACE2 was coated onto plates, and whether RBD or ACE was biotinylated and added in solution -and that the assay can be performed with just a drop of finger-stick blood.

T cell responses were investigated in a first study which showed commonly accepted rates of false negatives and false positives (or inadvertently infected subjects) using a wild type SARS-Cov2 S protein peptide pool derived from the whole amino acid sequence of wildtype protein which was available from the company Miltenyi at the time of the first study ( Figure   3 ). This first study also encompassed vaccinated as well as naturally infected individuals.

Similar to results for antibodies, T cell responses to this peptide pool were comparable in all vaccinees regardless of the type of vaccine used. Figure 3 Follow-up studies then compared peptide pools whose sequences comprised the whole amino acid sequence of wild type and alpha, beta, gamma and delta spike protein mutants, which were obtained from JPT peptides (Figures 4 -6) . Figure 4 shows the mean activation patterns of interferon (IFN)-gamma, Figure 5 of interleukin (IL)-2 and Figure 6 of tumour necrosis factor (TNF)-alpha for all subjects. Specific antibody reactivity and T cell response to SARS-CoV2 mutants alpha, beta, gamma and delta were comparable to wild type in all individuals, with no evidence for reduced responsiveness to any of the mutants (Figures 4 -6 ). In comparison, we also tested samples of non infected individuals who were all identified as negative (not shown in the Previous studies investigated antibody responses against SARS-CoV2 after COVID-19, and found decreases of antibody titers over time, that were assumed to correlate with decreasing immunity (10, 11) . Several recent studies investigated the long-term immune response after naturally occurring SARS-CoV2 infection or vaccination more broadly, including CD4 helper and CD8 effector T cells, memory B cells and others (12) (13) (14) . Following up on these recent studies, we investigated another cohort in the Munich area, Bavaria, Germany. Specifically, we measured antibody and T cell responses to S protein of recent variants of concern. The values reflect mean immune responses in the groups, whereas individual sera may contain proportions of antibodies to neutralizing epitopes that are sometimes conserved between strains.

Our results show reduced inhibition of delta mutant RBD -ACE2 interaction compared to wild type. To our knowledge, our study systematically compared for the first time inhibition assays which used labelled wt vs. mutant RBD and coated ACE2 on plates with those in which ACE2 was labelled and added in solution to wt vs. mutant RBD-coated plates. The results were comparable for the specific assay conditions which we established -this novel approach enables wide-scale multiplex-compliant assays. Both the direct interaction of anti-SARS-CoV2 serum antibodies of vaccinated or naturally infected subjects with RBD, and the All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 14, 2021. ; https://doi.org/10.1101/2021.09.07.21262725 doi: medRxiv preprint inhibition exerted by these antibodies on wt versus delta mutant RBD -ACE2 binding were measured by ELISA. The results using a drop of finger-stick full blood (about 30 µl) were well comparable to those using sera obtained by venous puncture, indicating that the assay can be up-scaled to a rapid point-of-care ELISA.

Our findings corroborate other recent studies which investigated delta mutant RBD by assays using live (pseudo)virus (15-19) , and resulted in comparable ratios of delta mutant versus wild type binding. However, these assays are time-consuming and require specialized Therefore, we also investigated T cell responses using peptide pools which were derived from the whole S sequence. This approach allowed for a broader investigation of anti-S protein immune responses. Generally, T cell responses to SARS-CoV2 are known to target a wide range of regions in the spike protein (25, 26). We found that significant immune responses were elicited by all investigated vaccines including mRNA (Moderna and BioNtech), and the vector-based vaccination with Vaxzevria (AstraZeneca). Our results show All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The correlation between individual specific T cell responses and anti-RBD antibodies was low, probably because B and T cell interaction is not linear, in accordance with previous studies (21).

Our results demonstrate that a combination of fast expression of recombinant proteins in mammalian cell systems and adaptive T cell assays allows for quick investigation of immune responses to virus variants within 3 months after their emergence, and may be possible within 6 weeks for future mutants. Identification of immune reactions against the current virus mutants and future variants of concern will allow to adapt vaccine strategies in order to provide population protection against the emerging lineages of concern of SARS-CoV-2. Our results imply that additional vaccination should be considered after natural infection with SARS-CoV2 in view of global mutant spread. The study summarizes a complementary diagnostic panel to assess immune reactions to vaccines.

Disclosure summary: All authors are employees of the biotech company ISAR Bioscience GmbH All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 14, 2021. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Significance levels were tested with Kruskal-Wallis test for non-parametric samples. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 14, 2021. ; https://doi.org/10.1101/2021.09.07.21262725 doi: medRxiv preprint preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 14, 2021. ; https://doi.org/10.1101/2021.09.07.21262725 doi: medRxiv preprint

SARS-CoV-2 vaccines in development

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against

-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

SARS CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Structural basis of receptor recognition by SARS-CoV-2

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients

Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19

T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals

All rights reserved. No reuse allowed without permission

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted